Literature DB >> 30151967

Two-year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with neurolymphomatosis.

Kari L Bjornard1, Vasiliki Leventaki2, Kim E Nichols1, John T Sandlund1, Susan Prockop3, Matthew J Ehrhardt1,4.   

Abstract

We describe a case of Epstein-Barr virus (EBV) positive, diffuse large B-cell lymphoma in a 2-year-old female who went on to develop relapsed/refractory central nervous system (CNS) disease, manifesting as cranial nerve neurolymphomatosis. Although her atypical presentation was thought to be associated with an immune deficiency, extensive work-up was negative. Despite subsequent treatment with third-party EBV-specific cytotoxic T-lymphocytes, she died of progressive disease. This case report raises questions as to whether tailored treatment approaches should be considered for atypical presentations of pediatric lymphoma (e.g., CNS and virus-associated).
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  EBV; lymphoma; neurolymphomatosis; pediatric

Mesh:

Year:  2018        PMID: 30151967      PMCID: PMC8244825          DOI: 10.1002/pbc.27415

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  18 in total

1.  Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

Authors:  Holger Schulz; Hendrik Pels; Ingo Schmidt-Wolf; Ulrich Zeelen; Ulrich Germing; Andreas Engert
Journal:  Haematologica       Date:  2004-06       Impact factor: 9.941

2.  Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.

Authors:  Sigal Grisariu; Batia Avni; Tracy T Batchelor; Martin J van den Bent; Felix Bokstein; David Schiff; Outi Kuittinen; Marc C Chamberlain; Patrick Roth; Anatoly Nemets; Edna Shalom; Dina Ben-Yehuda; Tali Siegal
Journal:  Blood       Date:  2010-04-05       Impact factor: 22.113

3.  Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab.

Authors:  Hui K Gan; Arun Azad; Lawrence Cher; Paul L R Mitchell
Journal:  Neuro Oncol       Date:  2009-12-24       Impact factor: 12.300

Review 4.  Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.

Authors:  Austen J J Worth; Charlotte J Houldcroft; Claire Booth
Journal:  Br J Haematol       Date:  2016-10-17       Impact factor: 6.998

5.  Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.

Authors:  Francesco Ceppi; Sheila Weitzman; Wilhelm Woessmann; Kimberly Davies; Alvaro Lassaletta; Bettina Reismüller; Karin Mellgren; Anne Uyttebroeck; Iris Maia; Shaker Abdullah; Natasha Miakova; Darryl Glaser; Richard Cohn; Oussama Abla; Andishe Attarbaschi; Sarah Alexander
Journal:  Am J Hematol       Date:  2016-04-04       Impact factor: 10.047

6.  Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Xinmiao Jiang; Lanping Xu; Yu Zhang; Fen Huang; Daihong Liu; Jin Sun; Chaoyang Song; Xinquan Liang; Zhiping Fan; Hongsheng Zhou; Min Dai; Can Liu; Qianli Jiang; Na Xu; Li Xuan; Meiqing Wu; Xiaojun Huang; Qifa Liu
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 7.  T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Authors:  Catherine M Bollard; Helen E Heslop
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

8.  Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.

Authors:  DeepakBabu Chellapandian; Rupali Das; Kristin Zelley; Susan J Wiener; Huaqing Zhao; David T Teachey; Kim E Nichols
Journal:  Br J Haematol       Date:  2013-05-21       Impact factor: 6.998

9.  Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

Authors:  S Goldman; L Smith; J R Anderson; S Perkins; L Harrison; M B Geyer; T G Gross; H Weinstein; S Bergeron; B Shiramizu; W Sanger; M Barth; J Zhi; M S Cairo
Journal:  Leukemia       Date:  2012-09-03       Impact factor: 11.528

10.  Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.

Authors:  Swati Naik; Sarah K Nicholas; Caridad A Martinez; Ann M Leen; Patrick J Hanley; Steven M Gottschalk; Cliona M Rooney; I Celine Hanson; Robert A Krance; Elizabeth J Shpall; Conrad R Cruz; Persis Amrolia; Giovanna Lucchini; Nancy Bunin; Jennifer Heimall; Orly R Klein; Andrew R Gennery; Mary A Slatter; Mark A Vickers; Jordan S Orange; Helen E Heslop; Catherine M Bollard; Michael D Keller
Journal:  J Allergy Clin Immunol       Date:  2016-02-24       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.